John H Greist1, James C Mundt1, Chad J Gwaltney1, James W Jefferson1, Kelly Posner1. 1. Dr. Greist is Clinical Adjunct Professor of Psychiatry at University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; Dr. Mundt is with the Center for Telepsychology, Madison, Wisconsin; Dr. Gwaltney is with ERT in Philadelphia, Pennsylvania; Dr. Jefferson is Clinical Adjunct Professor of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin; and Dr. Posner is with Columbia University, College of Physicians and Surgeons and New York State Psychiatric Institute, New York, New York.
Abstract
OBJECTIVE: Examine the ability of baseline electronic Columbia-Suicide Severity Rating Scale lifetime suicidal ideation and behavior categories to predict prospective reports of suicidal behavior in psychiatric and non-psychiatric research participants. DESIGN: Meta-analysis of 74,406 eC-SSRS assessments completed between September 2009 and December 2012. SETTING: Thirty-three clinical research studies that used the electronic Columbia-Suicide Severity Rating Scale to assess suicidal ideation and behavior at baseline and prospectively during follow-up visits. PARTICIPANTS: Records from 6,760 patients with psychiatric disorders (opioid dependence, generalized anxiety, major depressive, and posttraumatic stress disorders) and 2,077 nonpsychiatric disorder patients (chronic obstructive pulmonary disease, epilepsy, fibromyalgia, human immunodeficiency virus, insomnia, multiple sclerosis, osteoarthritis, pain/back pain, Parkinson's disease, restless leg syndrome) were analyzed. MEASUREMENTS: Electronic Columbia-Suicide Severity Rating Scale assessment of lifetime suicidal ideation (5 severity levels) and suicidal behavior (4 types) at baseline and prospectively reported suicidal behavior during study participation. RESULTS: Increasingly more severe lifetime suicidal ideation at baseline was associated with a progressively greater likelihood of prospectively reported suicidal behavior during study participation. Intent to act on suicidal ideation was most predictive of reports of suicidal behavior. Reports of lifetime suicidal behaviors at baseline also predicted subsequent suicidal behavior, and multiple lifetime behaviors monotonically increased prospective risk of suicidal behavior. Baseline suicidal ideation and behavior predicted future suicidal behavior in both psychiatric and non-psychiatric trials. CONCLUSIONS: Lifetime reports of suicidal ideation and/or behavior at baseline significantly increased risk of prospectively reporting suicidal behavior during research trial participation in both psychiatric and nonpsychiatric patients. Lifetime prevalence of suicidal ideation and behavior is higher among psychiatric patients, but also presents a safety concern among nonpsychiatric patients when reported.
OBJECTIVE: Examine the ability of baseline electronic Columbia-Suicide Severity Rating Scale lifetime suicidal ideation and behavior categories to predict prospective reports of suicidal behavior in psychiatric and non-psychiatric research participants. DESIGN: Meta-analysis of 74,406 eC-SSRS assessments completed between September 2009 and December 2012. SETTING: Thirty-three clinical research studies that used the electronic Columbia-Suicide Severity Rating Scale to assess suicidal ideation and behavior at baseline and prospectively during follow-up visits. PARTICIPANTS: Records from 6,760 patients with psychiatric disorders (opioid dependence, generalized anxiety, major depressive, and posttraumatic stress disorders) and 2,077 nonpsychiatric disorderpatients (chronic obstructive pulmonary disease, epilepsy, fibromyalgia, human immunodeficiency virus, insomnia, multiple sclerosis, osteoarthritis, pain/back pain, Parkinson's disease, restless leg syndrome) were analyzed. MEASUREMENTS: Electronic Columbia-Suicide Severity Rating Scale assessment of lifetime suicidal ideation (5 severity levels) and suicidal behavior (4 types) at baseline and prospectively reported suicidal behavior during study participation. RESULTS: Increasingly more severe lifetime suicidal ideation at baseline was associated with a progressively greater likelihood of prospectively reported suicidal behavior during study participation. Intent to act on suicidal ideation was most predictive of reports of suicidal behavior. Reports of lifetime suicidal behaviors at baseline also predicted subsequent suicidal behavior, and multiple lifetime behaviors monotonically increased prospective risk of suicidal behavior. Baseline suicidal ideation and behavior predicted future suicidal behavior in both psychiatric and non-psychiatric trials. CONCLUSIONS: Lifetime reports of suicidal ideation and/or behavior at baseline significantly increased risk of prospectively reporting suicidal behavior during research trial participation in both psychiatric and nonpsychiatric patients. Lifetime prevalence of suicidal ideation and behavior is higher among psychiatricpatients, but also presents a safety concern among nonpsychiatric patients when reported.
Authors: Kenneth A Kobak; Joshua Lipsitz; Janet B W Williams; Nina Engelhardt; Elizabeth Jeglic; Kevin M Bellew Journal: J Clin Psychopharmacol Date: 2007-10 Impact factor: 3.153
Authors: Madelyn S Gould; Frank A Marrocco; Marjorie Kleinman; John Graham Thomas; Katherine Mostkoff; Jean Cote; Mark Davies Journal: JAMA Date: 2005-04-06 Impact factor: 56.272
Authors: Madhukar H Trivedi; Stephen R Wisniewski; David W Morris; Maurizio Fava; Jackie K Gollan; Diane Warden; Andrew A Nierenberg; Bradley N Gaynes; Mustafa M Husain; James F Luther; Sidney Zisook; A John Rush Journal: J Clin Psychiatry Date: 2011-06 Impact factor: 4.384
Authors: James C Mundt; John H Greist; Alan J Gelenberg; David J Katzelnick; James W Jefferson; Jack G Modell Journal: J Psychiatr Res Date: 2010-06-02 Impact factor: 4.791
Authors: Benedetto Vitiello; Susan G Silva; Paul Rohde; Christopher J Kratochvil; Betsy D Kennard; Mark A Reinecke; Taryn L Mayes; Kelly Posner; Diane E May; John S March Journal: J Clin Psychiatry Date: 2009-04-21 Impact factor: 4.384
Authors: Marc Stone; Thomas Laughren; M Lisa Jones; Mark Levenson; P Chris Holland; Alice Hughes; Tarek A Hammad; Robert Temple; George Rochester Journal: BMJ Date: 2009-08-11